Current and Future Therapy of Hereditary Angioedema
Hereditary angioedema (HAE) is an autosomal dominant disorder, mostly due to C1 esterase inhibitor (C1-INH) deficiency, known by recurring angioedema attacks that are nonpruritic, not accompanying with urticaria, and involve the dermis, intestinal submucosa, and upper respiratory system. The angioed...
Main Author: | Öner Özdemir |
---|---|
Format: | Article |
Language: | English |
Published: |
KARE Publishing
2020-10-01
|
Series: | Southern Clinics of Istanbul Eurasia |
Subjects: | |
Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=scie&un=SCIE-01886 |
Similar Items
-
Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors
by: François Marceau, et al.
Published: (2019-05-01) -
Oxidative stress markers in patients with hereditary angioedema
by: Stefano R. Del Giacco, et al.
Published: (2017-07-01) -
Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
by: Xavier Charest-Morin, et al.
Published: (2018-10-01) -
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
by: Marc A. Riedl, et al.
Published: (2017-10-01) -
Hereditary angioedema: a disease seldom diagnosed by pediatricians
by: Régis de Albuquerque Campos, et al.
Published: (2021-03-01)